NCT06040814

Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation

Status unknown NA Last updated 18 September 2023

What this trial tests

NA trial testing Rehabilitation Training in Hepatic Encephalopathy in 120 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 December 2022
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	1 location across Taiwan

Drugs / interventions tested

• Rehabilitation Training

Conditions studied

• Hepatic Encephalopathy — all drugs for Hepatic Encephalopathy →

Sponsor

Chang Gung Memorial Hospital

Who can join

20 and older, any sex, with Hepatic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through this plan, it will provide many benefits to patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy, their family members, and the government in Taiwan:

1. To explore the changes of fecal microbiota before and after treatment such as resistance training rehabilitation in patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy as a reference for future fecal microbiota transplantation;
2. To measure the changes of sarcopenia level before and after rehabilitation;
3. To measure the changes of hepatic encephalopathy level before and after rehabilitation.

These study results will certainly bring updated diagnostic tool, latest treatment options, avoid serious sequelae and reduce medical expenditure.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
   Hou S, Yu J, Li Y, Zhao D, et al · · 2025 · cited 34× · PMID 40013938 · DOI 10.1002/advs.202413197
2. Gut microbiome and liver diseases.
   Xu J, Chen N, Li Z, Liu Y. · · 2025 · cited 6× · PMID 40242515 · DOI 10.1016/j.fmre.2024.09.007